- Home
- MDRR vs SYBX Comparison
MDRR vs SYBX Comparison
Compare MDRR & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- SYBX
- Stock Information
- Founded
- MDRR 2015
- SYBX N/A
- Country
- MDRR United States
- SYBX United States
- Employees
- MDRR N/A
- SYBX N/A
- Industry
- MDRR Real Estate Investment Trusts
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- SYBX Health Care
- Exchange
- MDRR Nasdaq
- SYBX Nasdaq
- Market Cap
- MDRR 17.1M
- SYBX 16.4M
- IPO Year
- MDRR 2018
- SYBX N/A
- Fundamental
- Price
- MDRR $13.15
- SYBX $1.67
- Analyst Decision
- MDRR
- SYBX
- Analyst Count
- MDRR 0
- SYBX 0
- Target Price
- MDRR N/A
- SYBX N/A
- AVG Volume (30 Days)
- MDRR 2.0K
- SYBX 17.6K
- Earning Date
- MDRR 11-11-2025
- SYBX 11-11-2025
- Dividend Yield
- MDRR 2.03%
- SYBX N/A
- EPS Growth
- MDRR N/A
- SYBX N/A
- EPS
- MDRR N/A
- SYBX N/A
- Revenue
- MDRR $9,649,145.00
- SYBX N/A
- Revenue This Year
- MDRR N/A
- SYBX N/A
- Revenue Next Year
- MDRR N/A
- SYBX N/A
- P/E Ratio
- MDRR N/A
- SYBX N/A
- Revenue Growth
- MDRR N/A
- SYBX N/A
- 52 Week Low
- MDRR $9.55
- SYBX $0.90
- 52 Week High
- MDRR $15.00
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- MDRR 50.62
- SYBX 54.91
- Support Level
- MDRR $13.05
- SYBX $1.62
- Resistance Level
- MDRR $14.00
- SYBX $1.74
- Average True Range (ATR)
- MDRR 0.31
- SYBX 0.09
- MACD
- MDRR -0.10
- SYBX -0.01
- Stochastic Oscillator
- MDRR 11.07
- SYBX 35.28
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.